Cargando…
The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
Osteosarcoma (OS) is the most common primary malignancy of bone and affects patients in the first two decades of life. The greatest determinant of survival is the presence of pulmonary metastatic disease. The role of epigenetic regulation in OS, specifically the biology of metastases, is unknown. Ou...
Autores principales: | Mu, Xiaodong, Brynien, Daniel, Weiss, Kurt R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346695/ https://www.ncbi.nlm.nih.gov/pubmed/25785263 http://dx.doi.org/10.1155/2015/290368 |
Ejemplares similares
-
Crafting Carbazole-Based Vorinostat and Tubastatin-A-like
Histone Deacetylase (HDAC) Inhibitors with Potent in Vitro and in
Vivo Neuroactive Functions
por: Reddy, R. Gajendra, et al.
Publicado: (2019) -
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010) -
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016) -
Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2013) -
Role of 5′TG3′-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition
por: Sharma, Ajay, et al.
Publicado: (2015)